Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 18, 2024
Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant TuberculosisJordan T Brooks, Belén P Solans, Agathe Béranger, et al.
The New England Journal of Medicine|January 10, 2003
Community-based therapy for multidrug-resistant tuberculosis in Lima, PeruCarole Mitnick, Jaime Bayona, Eda Palacios, et al.
The European Respiratory Journal|May 5, 2018
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South AfricaErika Mohr, Jennifer Hughes, Anja Reuter, et al.
Journal of Clinical Microbiology|February 16, 2022
Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort StudyHelen Cox, Galo A Goig, Zubeida Salaam-Dreyer, et al.
The Lancet. Microbe|November 12, 2021
Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology studyHelen Cox, Zubeida Salaam-Dreyer, Galo A Goig, et al.
American Journal of Respiratory and Critical Care Medicine|November 18, 2016
New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based RecommendationsElizabeth P Harausz, Anthony J Garcia-Prats, James A Seddon, et al.
Nature Communications|June 10, 2026
Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testingDebrah Vambe, Alexander Kay, Mangaliso Ziyane, et al.
Emerging Infectious Diseases|February 22, 2019
Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant TuberculosisMuhammad Osman, Elizabeth P Harausz, Anthony J Garcia-Prats, et al.
Research Square|April 8, 2025
ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisLinda Harrison, Gustavo E Velasquez, Russell R Kempker, et al.
Trials|August 15, 2025
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosisLinda J Harrison, Gustavo E Velásquez, Russell R Kempker, et al.
Pageof 9